ERBB2 and gastric cancer: As immunotherapy based on the use of immune checkpoint inhibitors is successfully entering the field of gastric cancer treatment (see paragraph “Immune checkpoint inhibition”), combinations of HER2-targeted therapy with immunotherapy are on the horizon.